HQL-79
HQL-79, a potent, selective and orally active human hematopoietic prostaglandin D synthase (H-PGDS) inhibitor, highly selectively inhibits the synthesis of PGD2, and acts as an anti-allergic agent, with a Kd of 0.8 μM and an IC50 of 6 μM. Shows no obvious effect on COX-1, COX-2, m-PGES, or L-PGDS[1].
Product Specifications
CAS Number
162641-16-9
UNSPSC
12352005
Target
PGE synthase
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/hql-79.html
Purity
99.89
Solubility
DMSO : 2 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
N1(CCCC2=NN=NN2)CCC(OC(C3=CC=CC=C3)C4=CC=CC=C4)CC1
Molecular Formula
C22H27N5O
Molecular Weight
377.48
References & Citations
[1]Aritake K, et al. Structural and functional characterization of HQL-79, an orally selective inhibitor of human hematopoietic prostaglandin D synthase. J Biol Chem. 2006 Jun 2;281 (22) :15277-86. Epub 2006 Mar 17.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
